Skip to main
TBI
TBI logo

TrueBlue (TBI) Stock Forecast & Price Target

TrueBlue (TBI) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TrueBlue Inc. demonstrated a modest year-over-year revenue growth of 2%, primarily fueled by strong performance in the commercial sector, which experienced double-digit growth. Additionally, the company achieved a 50 basis point improvement in adjusted EBITDA margin, rising to 0.7%, reflecting the effectiveness of its strategic cost management initiatives. These factors, combined with the solid contribution from the PeopleReady segment, support a positive outlook for TrueBlue's financial performance moving forward.

Bears say

TrueBlue Inc. is experiencing a significant decline in financial performance, with an adjusted EBITDA margin that has dropped 320 basis points year-over-year to 5.2%, primarily due to reduced operating leverage linked to declining organic revenues. The company’s PeopleReady segment, which generates the majority of its revenue, reported a 5% year-over-year revenue decrease, surpassing the projected decline of 3%, indicating ongoing weakness across various client verticals. Additionally, TrueBlue's second-quarter report highlighted an adjusted loss per share of $(0.07), reflecting further financial distress and compounding investor concerns.

TrueBlue (TBI) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TrueBlue and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TrueBlue (TBI) Forecast

Analysts have given TrueBlue (TBI) a Buy based on their latest research and market trends.

According to 1 analysts, TrueBlue (TBI) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TrueBlue (TBI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.